These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2990768)

  • 21. Kaliuretic peptide: the most potent inhibitor of Na(+)-K+ ATPase of the atrial natriuretic peptides.
    Chiou S; Vesely DL
    Endocrinology; 1995 May; 136(5):2033-9. PubMed ID: 7720651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Higher plasma Na+,K+-ATPase inhibitory activity in essential hypertensive patients.
    Vasdev S; Fernandez PG; Longerich L; Gault H
    Can J Cardiol; 1989; 5(5):249-54. PubMed ID: 2547501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Na-K-ATPase inhibitor dissociated from hypertension-associated plasma protein.
    Weiler EW; Khalil-Manesh F; Gonick HC; Prins BA; Purdy RE; Sensharma DK
    Am J Hypertens; 1999 Apr; 12(4 Pt 1):364-73. PubMed ID: 10232496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natriuretic hormone - a circulating inhibitor of sodium- and potassium-activated adenosine triphosphatase. Its potential role in body fluid and blood pressure regulation.
    Kramer HJ
    Klin Wochenschr; 1981 Nov; 59(22):1225-30. PubMed ID: 6273645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endogenous plasma Na,K-ATPase inhibitory activity and digoxin like immunoreactivity after acute myocardial infarction.
    Bagrov AYa ; Fedorova OV; Maslova MN; Roukoyatkina NI; Ukhanova MV; Zhabko EP
    Cardiovasc Res; 1991 May; 25(5):371-7. PubMed ID: 1649699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of sodium intake on the excretion of urinary natriuretic factor in essential hypertensives.
    Morise T; Miyamori I; Hifumi S; Okamoto S; Ikeda M; Takeda Y; Koshida H; Yasuhara S; Takeda R
    Endocrinol Jpn; 1985 Jun; 32(3):405-11. PubMed ID: 2995016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ouabain-like Na+,K(+)-ATPase inhibitory activity of a plasma extract in normal pregnancy and pregnancy induced hypertension.
    Miyagi H; Higuchi M; Nakayama M; Moromizato H; Sakanashi M
    Jpn J Pharmacol; 1991 Dec; 57(4):571-81. PubMed ID: 1666421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Purification and characterization of human urine-derived digitalis-like factor.
    Goto A; Yamada K; Ishii M; Yoshioka M; Ishiguro T; Eguchi C; Sugimoto T
    Biochem Biophys Res Commun; 1988 Aug; 154(3):847-53. PubMed ID: 2841934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Purification of a Na+/K+ ATPase inhibitor from borderline hypertensives' plasma.
    Boschi S; Borghi C; Munarini A; Costa FV; Lu ZR; deVries D; Ambrosioni E
    Biochem Biophys Res Commun; 1990 Jun; 169(2):360-8. PubMed ID: 2162662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Observations on the "cascade" of Na-K-ATPase inhibitory and digoxin-like immunoreactive material in human urine: possible relevance to essential hypertension.
    Weiler E; Tuck M; Gonick HC
    Clin Exp Hypertens A; 1985; 7(5-6):809-36. PubMed ID: 4017267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipids as endogenous Na,K-ATPase inhibitors in plasma of healthy individuals and in dialysis dependent patients.
    Vasdev SC; Longerich L; Prabhakaran VM; Triggle CR; Gault MH
    Clin Biochem; 1989 Aug; 22(4):313-9. PubMed ID: 2550162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dimethyl sulfoxide inhibits renal Na(+)-K(+)-ATPase at a site different from ouabain and atrial peptides.
    Chiou S; Vesely DL
    Life Sci; 1995; 57(10):945-55. PubMed ID: 7643719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sodium transport inhibitor from bovine hypothalamus.
    Haupert GT; Sancho JM
    Proc Natl Acad Sci U S A; 1979 Sep; 76(9):4658-60. PubMed ID: 228304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ouabainlike factor in Milan hypertensive rats.
    Ferrandi M; Minotti E; Salardi S; Florio M; Bianchi G; Ferrari P
    Am J Physiol; 1992 Oct; 263(4 Pt 2):F739-48. PubMed ID: 1329560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of a low molecular weight Na-K-ATPase inhibitor of urinary origin.
    Weiler EW; Gonick HC; Prins BA; Purdy RE; Weber MA
    Am J Med Sci; 1994 Jan; 307(1):27-35. PubMed ID: 8291503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endogenous digoxin-like activity of mammalian-lignans and their derivatives.
    Hirano T; Oka K; Naitoh T; Hosaka K; Mitsuhashi H
    Res Commun Chem Pathol Pharmacol; 1989 May; 64(2):227-40. PubMed ID: 2544967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stability of [3H]ouabain binding to the (Na+ + K+)-ATPase solubilized with C12E8.
    Inaba M; Maede Y
    Biochim Biophys Acta; 1985 Aug; 818(2):267-70. PubMed ID: 2992592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Marinobufagenin, an endogenous alpha-1 sodium pump ligand, in hypertensive Dahl salt-sensitive rats.
    Fedorova OV; Kolodkin NI; Agalakova NI; Lakatta EG; Bagrov AY
    Hypertension; 2001 Feb; 37(2 Pt 2):462-6. PubMed ID: 11230319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relation of the natriuretic hormone to essential hypertension.
    de Wardener HE; MacGregor GA
    Postgrad Med J; 1983; 59 Suppl 2():74-7. PubMed ID: 6310538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predominance of high molecular weight plasma Na(+)-K(+)-ATPase inhibitor in essential hypertension.
    Gonick HC; Weiler EW; Khalil-Manesh F; Weber MA
    Am J Hypertens; 1993 Aug; 6(8):680-7. PubMed ID: 8217031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.